The French auditory biopharmaceutical company has established Cilcare K.K. in Japan, positioning Tokyo as its hub for regional growth.

Cilcare, a biopharmaceutical company specializing in auditory science, has announced the establishment of Cilcare K.K., a new subsidiary based in Tokyo. The move extends the Montpellier, France-headquartered company’s footprint to Asia, following its earlier expansion into North America, and signals a broader push to capture growing opportunities in Japan’s hearing health sector.

Japan as a Strategic Market

Japan’s aging population and national focus on prevention, healthy aging, and quality of life have elevated hearing health as a key priority within the country’s healthcare landscape. Hearing loss is recognized as a major modifiable risk factor for dementia — a connection further reinforced by the 2024 Lancet Commission — adding urgency to the development of preventive and therapeutic solutions in the region.

Cilcare brings to Japan more than 350 collaborative projects worldwide in auditory science, along with R&D operations spanning France and the United States. The company’s portfolio includes Synapsound AI, a proprietary AI-based auditory analytics platform designed to identify novel biomarkers and enable earlier detection and characterization of neurological diseases.

Building on an Existing Japanese Presence

The launch of Cilcare K.K. builds on a foundation the company has been developing in Japan for over a decade. Cilcare’s 2024 strategic partnership with Shionogi — covering the co-development and commercialization of CIL001 and CIL003 — demonstrated early traction in the Japanese market. The Hearing Review previously covered Cilcare and Shionogi’s option agreement for hearing disorder treatment.

A decade of engagement with Japanese universities and key opinion leaders has laid the groundwork for the new subsidiary, which Cilcare says will serve as a platform to accelerate partnerships across Asia-Pacific and connect regional stakeholders with its global pharmaceutical and biotechnology network.

Aurore Marie to Lead Japan and Asia Operations

Aurore Marie has been named general manager, Japan & Asia, to lead Cilcare K.K. Marie previously played a central role in establishing Cilcare’s US presence in Boston and brings expertise in auditory science alongside cross-cultural leadership experience.

“I am very excited to start this new chapter for Cilcare in Japan. After many years working with Japanese partners, and even learning Japanese along the way, I look forward to building our activities from Tokyo. The opportunities in hearing health and healthy ageing across Asia-Pacific are immense,” says Marie, in a release.

“Cilcare is becoming a truly global company, with strong roots in Europe and the United States and now a dedicated presence in Japan. Having a local team in Tokyo positions us to capture the significant opportunities ahead in hearing health,” says Celia Belline, CEO and co-founder of Cilcare, in a release.

Broader Context for Cilcare’s Global Expansion

The Tokyo subsidiary is the latest in a series of strategic moves by Cilcare to expand its international reach. The Hearing Review has previously reported on the company’s US clinical trial for a tinnitus drug and expanded research capacity, its updated license agreement with Sanofi, and its funding secured to advance cochlear synaptopathy clinical trials.

Cilcare acknowledged the support of institutional partners in Japan, including Business France, the French Chamber of Commerce and Industry in Japan (CCIFJ), the Enterprise Europe Network (EEN), the Occitanie Region and its Bureau de l’Occitanie in Tokyo, and JETRO (Japan External Trade Organization).

For more information, visit cilcare.com.